Idoroenyi Amanam to Precursor Cell Lymphoblastic Leukemia-Lymphoma
This is a "connection" page, showing publications Idoroenyi Amanam has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Connection Strength
1.391
-
Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis. Leuk Lymphoma. 2022 12; 63(13):3268-3270.
Score: 0.754
-
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025 May 13; 9(9):2159-2172.
Score: 0.228
-
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 06; 98(6):848-856.
Score: 0.196
-
Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. Clin Lymphoma Myeloma Leuk. 2020 06; 20(6):e320-e327.
Score: 0.159
-
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. Bone Marrow Transplant. 2024 Nov; 59(11):1542-1551.
Score: 0.054